share_log

Essex Bio-Technology Unit's Co-Developed Drug Completes LPLV for Phase 3 Clinical Study

Essex Bio-Technology Unit's Co-Developed Drug Completes LPLV for Phase 3 Clinical Study

埃塞克斯生物科技單位共同開發的藥物完成了第三階段臨牀研究的LPLV。
MT Newswires ·  01/06 20:14

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論